10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares in UK-based antibiotics developer Motif Bio are now worth just a tenth of their value of four months ago after more bad news about iclaprim, the company’s lead product. 7 June 2019
The US Food and Drug Administration yesterday approved marketing of autoinjector and prefilled safety syringe versions of GlaxoSmithKline's asthma drug Nucala (mepolizumab), enabling self-administration of the monthly dose of the interleukin (IL)-5 inhibitor. 7 June 2019
Australian biotech firm Benitec Biopharma today announced the termination of the license and collaboration agreement with Axovant Sciences. 6 June 2019
French biotech Transgene has announced the publication of two articles highlighting the potential of its virus-based immunotherapies for the treatment of solid tumors. 6 June 2019
AstraZeneca today announced positive results from the Phase III ELEVATE-TN trial of Calquence (acalabrutinib) in patients with previously-untreated chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults. 6 June 2019
Boston, USA-based Third Rock Ventures today announced today the closing of Third Rock Ventures V, raising $770 million in an oversubscribed fund, and marking the largest in its 12-year history. 6 June 2019
Germany-headquartered clinical-stage biotech InflaRx (Nasdaq: IFRX) saw its shares crash nearly 92% to $3.06 by close of trading on Wednesday, after the company revealed that IVX-1, its potential treatment for an inflammatory skin disorder, failed to demonstrate statistical significance compared to placebo. 6 June 2019
After 20 years in various leadership roles with US pharma major Eli Lilly, Pete Salzmann has left to take the top job at a company specializing in autoimmune diseases. 6 June 2019
It has now been nearly three years since Orkambi (lumacaftor-ivacaftor), the treatment for cystic fibrosis (CF) patients who have the F508del mutation, was first ruled too expensive for use on the UK’s National Health Service (NHS). 5 June 2019
The headline-grabbing results on AMG 510, the first KRASG12C inhibitor to reach the clinical stage, were not the only data to be shared by US biotech Amgen on its early-stage oncology pipeline. 5 June 2019
AbbVie has presented data from the CLL14 trial, examining Venclexta (venetoclax) plus Roche’s CD20 blocker Gazyva (obinutuzumab), as a first-line therapy for chronic lymphocytic leukaemia (CLL). 5 June 2019
California-based rare diseases specialist Eiger BioPharmaceuticals today announced the appointment of Jeysen Yogaratnam as vice president of global hepatitis Delta virus (HDV) clinical development. 5 June 2019
Independent French drugmaker Servier has linked up with Yposkesi, a Contract Development & Manufacturing Organization (CDMO) to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development. 5 June 2019
Celgene has provided cause for celebration for Bristol-Myers Squibb, which is set to take over the US biotech company, and its partner Acceleron Pharma. 5 June 2019
The US Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for RVT-802, a novel investigational tissue-based regenerative therapy designed to treat pediatric congenital athymia, and granted Priority Review. 5 June 2019
Japan’s largest drugmaker Takeda Pharmaceutical has announced new data from an ad-hoc analysis of the Phase III HELP Study, designed to evaluate the onset of action for Takhzyro (lanadelumab) during days 0-69 of treatment. 5 June 2019
The US Food and Drug Administration has approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. 5 June 2019
Privately-held anti-infective drug specialist Prokaryotics has inked an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation. 5 June 2019
Adding to a list of significant collaborations with big pharma, USA-based biotech Arvinas has now signed a collaboration with German pharma major Bayer, with the news sending the US firm’s share up more than 8% to $21.66 in early trading today. 4 June 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024